For Medical Professionals

Tinefcon’s successful clinical trial was carried out under exacting standards:

• A double-blind, parallel group, placebo-controlled, prospective, multi-center study in subjects with moderate to severe cases, (subjects with a PASI score > 10)
• Evaluation of adverse events, physical examination, clinically significant changes in laboratory parameters and ECG histopathological analysis and gene expression profiling carried out to support the efficacy
• Tinefcon demonstrated improvement in a number of subjects (PASI 75 response & PASI 90 response) along with an improvement in histopathology analysis
• Exhibited a promising safety profile
• Initial efficacy observed over a 3 month treatment period
• A new Phase IV follow up study launched in September 2010 with 200 patients